Variable progression of HIV-associated dementia

Neurology

Volumn 50, Issue 6, 1998, Pages 1814-1820

  Bouwman, F H ^a   Skolasky, R L ^a   Hes, D ^a   Selnes, O A ^a   Glass, J D ^a   Nance Sproson, T E ^a   Royal, W ^a   Dal Pan, G J ^a   McArthur, Justin C ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; GLYCOPROTEIN GP 41;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AIDS RELATED COMPLEX; ARTICLE; COGNITION; DEMENTIA; DETERIORATION; DISABILITY; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; INTRAVENOUS DRUG ABUSE; MACROPHAGE ACTIVATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PSYCHOMOTOR RETARDATION; SURVIVAL TIME;

EID: 0031779683     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.6.1814     Document Type: Article

References (47)

1. Chaisson RE, Keruly JC, Moore RD. Race, sex, drug use, and progression of human immunodeficiency virus disease. N Engl J Med 1995;333:751-756.
2. Operskalski EA, Stram DO, Lee H, et al. Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. J Infect Dis 1995;172:648-655.
3. Saah AJ, Munoz A, Kuo V, et al. Predictors of risk of development of acquired immunodeficiency syndrome within 24 months among gay men seropositive for human immunodeficiency virus type 1: a report from the Multicenter AIDS Cohort Study. Am J Epidemiol 1992;135:1147-1155.
4. Ward JW, Bush TJ, Perkins HA, et al. The natural history of transfusion-associated infection with human immunodeficiency virus. Factors influencing the rate of progression to disease. N Engl J Med 1989;321:947-952.
5. Von Overbeck J, Egger M, Smith GD, et al. Survival in HIV infection: do sex and category of transmission matter? Swiss HIV Cohort Study. AIDS 1994;8:1307-1313.
6. McArthur JC, Hoover DR, Bacellar H, et al. Dementia in AIDS patients: incidence and risk factors. Neurology 1993;43: 2245-2252.
7. Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol 1986;19:517-524.
8. McArthur JC. Neurologic manifestations of AIDS. Medicine (Baltimore) 1987;66:407-437.
9. Portegies P, Enting RH, de Gans J, et al. Presentation and course of AIDS dementia complex: ten years of follow-up in Amsterdam, the Netherlands. AIDS 1993;7:669-675.
10. Tozzi V, Narciso P, Galgani S, et al. Effects of zidovudine in 30 patients with mild to end-stage AIDS dementia complex. AIDS 1993;7:683-692.
11. Harrison MJG, McArthur JC. AIDS and neurology. Edinburgh: Churchill Livingstone, 1995.
12. Dreyer EB, Kaiser PK, Offermann JT, Lipton SA. HIV-1 coat protein neurotoxicity prevented by calcium channel antagonists. Science 1990;248:364-367.
13. Adamson DC, Wildemann B, Sasaki M, et al. Immunologic nitric oxide synthase: elevation in severe AIDS dementia and induction by HIV-1 coat protein, gp41. Science 1996;274: 1917-1921.
14. Brenneman DE, Westbrook GL, Fitzgerald SP, et al. Neuronal cell killing by the envelope protein of HIV and its prevention by vasoactive intestinal peptide. Nature 1988;335:639-642.
15. Lipton SA, Sucher NJ, Kaiser PK, Dreyer EB. Synergistic effects of HIV coat protein and NMDA-receptor mediated neurotoxicity. Neuron 1991;7:111-118.
16. Glass JD, Fedor H, Wesselingh SL, McArthur JC. Immunocytochemical quantitation of HIV in the brain: correlations with HIV-associated dementia. Ann Neurol 1995;38:755-762.
17. Portegies P. The neurology of HIV-1 infection. London: Medi-Tech Media, 1995.
18. Sacktor NC, McArthur JC. Prospects for therapy of HIV-associated neurologic disease. J Neurovirol 1997;3:89-101.
19. Janssen RS, Nwanyanwu OC, Selik RM, Stehr-Green JK. Epidemiology of human immunodeficiency virus encephalopathy in the United States. Neurology 1992;42:1472-1476.
20. Janssen RS, Saykin AJ, Cannon L, et al. Neurological and neuropsychological manifestations of HIV-1 infection: association with AIDS-related complex but not asymptomatic HIV-1 infection. Ann Neurol 1989;26:592-600.
21. Price RW. Understanding AIDS dementia complex: the challenge of HIV and its effects on the central nervous system. In: Price RW, Perry SW, eds. HIV, AIDS and the brain. New York: Raven Press, 1994.
22. Boller F, Becker JT, Holland AL, Forbes MM, Hood PC, McGonigle-Gibson KL. Predictors of decline in Alzheimer's disease. Cortex 1991;27:9-17.
23. Mortimer JA, Ebbitt B, Jun SP, Finch MD. Predictors of cognitive and functional progression in patients with probable Alzheimer's disease. Neurology 1992;42:1689-1696.
24. Almkvist O, Backman L, Basun H, Wahlund LO. Patterns of neuropsychological performance in Alzheimer's disease and vascular dementia. Cortex 1993;29:661-673.
25. Hogan DB, Thierer DE, Ebly EM, Parhad IM. Progression and outcome of patients in a Canadian dementia clinic. Can J Neurol Sci 1994;21:331-338.
26. Bracco L, Gallato R, Grigoletto F, et al. Factors affecting course and survival in Alzheimer's disease. A 9-year longitudinal study. Arch Neurol 1994;51:1213-1219.
27. Stern Y, Albert M, Brandt J, et al. Utility of extrapyramidal signs and psychosis as predictors of cognitive and functional decline, nursing home admission, and death in Alzheimers' disease: prospective analyses from the Predictors Study. Neurology 1994;44:2300-2307.
28. Farrer LA, Cupples LA, Van Duijn CM, Connor-Lacke L, Kiely DK, Growdon JH. Rate of progression of Alzheimer's disease is associated with genetic risk. Arch Neurol 1995;52: 918-923.
29. Appel V, Stewart SS, Smith G, Appel SH. A rating scale for amyotrophic lateral sclerosis: description and preliminary experience. Ann Neurol 1987;22:328-333.
30. Haverkamp LJ, Appel V, Appel SH. Natural history of amyotrophic lateral sclerosis in a database population. Validation of a scoring system and a model for survival prediction. Brain 1995;118:707-719.
31. Janssen RS, Cornblath DR, Epstein LG, et al. Nomenclature and research case definitions for neurological manifestations of human immunodeficiency virus type-1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 1991;41:778-785.
32. Price RW, Brew BJ. The AIDS dementia complex. J Infect Dis 1988;158:1079-1083.
33. Glass JD, Wesselingh SL, Selnes OA, McArthur JC. Clinicalneuropathologic correlation in HIV-associated dementia. Neurology 1993;43:2230-2237.
34. Folstein MF, Folstein SE, McHugh PR. Mini-Mental State: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
35. Power C, McArthur JC, Johnson RT, et al. Demented and non-demented patients with AIDS differ in brain-derived human immunodeficiency virus type 1 envelope sequences. J Virol 1994;68:4643-4649.
36. Levy JA. The transmission of HIV and factors influencing progression to AIDS (review). Am J Med 1993;95:86-100.
37. Satz P, Morgenstern H, Miller EN, et al. Low education as a possible risk factor for cognitive abnormalities in HIV-1: findings from the Multicenter AIDS Cohort Study (MACS). JAIDS 1993;6:503-511.
38. Rothenberg R, Woelfel M, Stoneburner R, Milberg J, Parker R, Truman B. Survival with the acquired immunodeficiency syndrome: experience with 5833 cases in New York City. N Engl J Med 1987;317:1297-1302.
39. Concha M, Selnes OA, Vlahov D, et al. Comparison of neuropsychologic performance between AIDS-free injecting drug users and homosexual men. Neuroepidemiology 1997;16:78-85.
40. Selnes OA, McArthur JC, Royal W, et al. HIV-1 infection and intravenous drug use: longitudinal neuropsychological evaluation of asymptomatic subjects. Neurology 1992;42:1924-1930.
41. Palenicek J, Nelson KE, Vlahov D, Galai Y, Cohn S, Saah AJ. Comparison of clinical symptoms of human immunodeficiency virus disease between intravenous drug users and homosexual men. Arch Intern Med 1993;153:1806-1812.
42. An SF, Ciardi A, Giometto B, Scaravilli T, Gray F, Scaravilli F. Investigation on the expression of major histocompatibility complex class II and cytokines and detection of HIV-1 DNA within brains of asymptomatic and symptomatic HIV-1-positive patients. Acta Neuropathol 1996;91:494-503.
43. Adamson DC, McArthur JC, Dawson T, Dawson V. Rapid progression of HIV-associated dementia is associated with CNS iNOS and gp41 expression. Presented at the fourth Conference on Retroviruses and Opportunistic Infections, January 1997, Washington, DC.
44. Portegies P, de Gans J, Lange JM, et al. Declining incidence of AIDS dementia complex after introduction of zidovudine treatment [published erratum appears in BMJ 1989 (Nov. 4);299:1141]. BMJ 1989;299:819-821.
45. Nordic Medical Research Councils HIV Therapy Group. Double blind dose-response study of zidovudine in AIDS and advanced HIV infection. Br Med J 1992;304:13-17.
46. Yarchoan R, Pluda JM, Thomas RV, et al. Long-term toxicity/ activity profile of 2′,3′-dideoxyinosine in AIDS and AIDS-related complex. Lancet 1990;336:526-529.
47. Terasaki T, Pardridge WM. Restricted transport of 3′-azido-3′-deoxythymidine and dideoxynucleosides through the blood-brain barrier. J Infect Dis 1988;3:630-632.